Articles related to IMMUNOTHERAPY

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

“Having achieved a complete pathologic response was the best-case scenario that we could have hoped for.”

The phase 3 ALLELE trial demonstrated tabelecleucel’s potential with a 50.7% overall response rate and median duration of response of 23.0 months in EBV+ PTLD patients.

Combined omalizumab-OIT therapy demonstrated an impressive 50-percentage-point advantage over placebo in food challenge success rates for children with multiple food allergies.

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.